Cancer Causes & Control

, Volume 9, Issue 1, pp 83–88

Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States)

Authors

  • Lynn Rosenberg
    • School of Public HealthBoston University School of Medicine
  • R. Sowmya Rao
    • School of Public HealthBoston University School of Medicine
  • Julie R. Palmer
    • School of Public HealthBoston University School of Medicine
  • Brian L. Strom
    • Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, and Division of General Internal Medicine of the Department of MedicineUniversity of Pennsylvania School of Medicine
  • Ann Zauber
    • Department of Epidemiology and BiostatisticsMemorial Sloan-Kettering Cancer Center
  • M. Ellen Warshauer
    • Department of Public HealthCornell Medical Center, New York Hospital
  • Paul D. Stolley
    • Department of Epidemiology and Preventive MedicineUniversity of Maryland School of Medicine
  • Samuel Shapiro
    • School of Public HealthBoston University School of Medicine
Article

DOI: 10.1023/A:1008805505154

Cite this article as:
Rosenberg, L., Sowmya Rao, R., Palmer, J.R. et al. Cancer Causes Control (1998) 9: 83. doi:10.1023/A:1008805505154

Abstract

Experimental and epidemiologic evidence have suggested that phenacetin use increases the risk of transitional cell cancers of the urinary tract. The drug is no longer marketed but a commonly used metabolite, acetaminophen, has been linked recently to an increased risk of renal cancer. We assessed the relation of acetaminophen use to the risk of transitional cell cancer of the urinary tract and of renal cell cancer with data from a hospital-based study of cancers and medication use conducted from 1976-96 in the eastern United States. We compared 498 cases of transitional cell cancer and 383 cases of renal cell cancer with 8,149 noncancer controls and 6,499 cancer controls and controlled confounding factors with logistic regression. For transitional cell cancer, the relative risk (RR) estimate for regular acetaminophen use that had begun at least a year before admission was 1.1 (95 percent confidence interval [CI] = 0.6-1.9) based on noncancer controls, and 0.9 (CI = 0.5-1.6) based on cancer controls. RR estimates for use that lasted at least five years, and for nonregular use, were also close to 1.0. For renal cell cancer, the corresponding estimates were again close to 1.0. Our results suggest that acetaminophen, as used in present study population, does not influence the risk of transitional cell cancer of the urinary tract or of renal cell cancer.

Acetaminophenkidney neoplasmsrenal cell carcinomaUnited States

Copyright information

© Chapman and Hall 1998